ResearcherNebraska Medical CenterNo recent work listed
Andrew C. Cannon
Matched on ORCID iD 0000-0002-5892-8907; OpenAlex author ID A5037086401; NIH RePORTER profile ID 14836884. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 2, last author 0)
- Trials
- 0
- Grants
- 1
- Labs led
- 0
- Collaborators
- 20
2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper, 1 grant · 2021: 2 papers · 2022: none · 2023: 1 paper
Papers 7
- Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. Co-author DOI 10.1038/s41388-022-02587-1↗
- Molecular mechanisms of pancreatic myofibroblast activation in chronic pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-021-01800-4↗
- Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/1078-0432.ccr-21-1591↗
- CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-20-1359↗
- Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. Co-author DOI 10.18632/genesandcancer.171↗
- Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. First author DOI 10.18632/oncotarget.25036↗
- MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/14728222.2017.1323880↗
Grants 1
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Surinder K. Batra · 7 shared papers, 2017–2023 · strength 0.78
- Paper Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. DOI 10.1038/s41388-022-02587-1↗
- Paper Molecular mechanisms of pancreatic myofibroblast activation in chronic pancreatitis and pancreatic ductal adenocarcinom… DOI 10.1007/s00535-021-01800-4↗
- Paper Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-21-1591↗
- Sushil Kumar K · 6 shared papers, 2017–2023 · strength 0.65
- Paper Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. DOI 10.1038/s41388-022-02587-1↗
- Paper Molecular mechanisms of pancreatic myofibroblast activation in chronic pancreatitis and pancreatic ductal adenocarcinom… DOI 10.1007/s00535-021-01800-4↗
- Paper CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarci… DOI 10.1158/1078-0432.ccr-20-1359↗
- Christopher M. Thompson · 5 shared papers, 2018–2023 · strength 0.63
- Paper Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. DOI 10.1038/s41388-022-02587-1↗
- Paper Molecular mechanisms of pancreatic myofibroblast activation in chronic pancreatitis and pancreatic ductal adenocarcinom… DOI 10.1007/s00535-021-01800-4↗
- Paper Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-21-1591↗
- Rakesh Bhatia · 5 shared papers, 2017–2023 · strength 0.60
- Paper Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. DOI 10.1038/s41388-022-02587-1↗
- Paper Molecular mechanisms of pancreatic myofibroblast activation in chronic pancreatitis and pancreatic ductal adenocarcinom… DOI 10.1007/s00535-021-01800-4↗
- Paper Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-21-1591↗
- Maneesh Jain · 3 shared papers, 2017–2023 · strength 0.32
- Paper Muc4 loss mitigates epidermal growth factor receptor activity essential for PDAC tumorigenesis. DOI 10.1038/s41388-022-02587-1↗
- Paper Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. DOI 10.18632/genesandcancer.171↗
- Paper MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma. DOI 10.1080/14728222.2017.1323880↗
- Pranita Atri · 3 shared papers, 2018–2021 · strength 0.31
- Paper Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-21-1591↗
- Paper CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarci… DOI 10.1158/1078-0432.ccr-20-1359↗
- Paper Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. DOI 10.18632/oncotarget.25036↗
- Bradley R. Hall · 3 shared papers, 2017–2018 · strength 0.25
- Paper Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. DOI 10.18632/genesandcancer.171↗
- Paper Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. DOI 10.18632/oncotarget.25036↗
- Paper MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma. DOI 10.1080/14728222.2017.1323880↗
- Lynette M. Smith · 2 shared papers, 2018–2021 · strength 0.20
- Koelina Ganguly · 1 shared paper, 2023 · strength 0.15
- Naveenkumar Perumal · 1 shared paper, 2023 · strength 0.15
- Jesse L. Cox · 1 shared paper, 2023 · strength 0.15
- Xiaoqi Li · 1 shared paper, 2023 · strength 0.15
- Satyanarayana Rachagani · 1 shared paper, 2023 · strength 0.15
- Joyce C. Solheim · 1 shared paper, 2021 · strength 0.15
- Sushil Kumar · 1 shared paper, 2021 · strength 0.12
- H. Carlo Maurer · 1 shared paper, 2020 · strength 0.11
- Kenneth P. Olive · 1 shared paper, 2020 · strength 0.11
- Chandrakanth Are · 1 shared paper, 2018 · strength 0.08
- Apar Kishor Ganti · 1 shared paper, 2018 · strength 0.08
- Shailendra Kumar Gautam · 1 shared paper, 2017 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.